| Name | Title | Contact Details |
|---|
A World Leader in Pediatric Healthcare Founded in 1950 by Variety Clubs International, Nicklaus Children s Hospital, formerly Miami Children s Hospital, operates South Florida’s only licensed specialty hospital exclusively for children, with more than 650 attending physicians and over 130 pediatric sub-specialists. The 289-bed nonprofit hospital is renowned for excellence in all aspects of pediatric medicine and routinely has many programs ranked among the nation’s best by U.S. News and World Report. The organization has grown and evolved into the Miami Children s Health System (MCHS) which includes Miami Children s Health Foundation, the organization s 501c3 fundraising arm; a network of eight nonprofit outpatient centers situated in Miami-Dade, Broward and Palm Beach counties; Pediatric Specialty Group, Inc., a nonprofit physician practice subsidiary; a management services organization, and an ambulatory surgery center (opening soon), as well as an e-commerce line of children s wellness and safety products that support the hospital s mission of serving the region’s pediatric population. MCHS is the region’s only healthcare system exclusively for children.
Women's Health Initiative is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southeastern Medical Technologies is a Savannah, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oak Hill Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Oak Hill Hospital is based in Brooksville, FL. You can find more information on Oak Hill Hospital at www.oakhillhospital.com
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.